Abstract: This invention provides a combined pharmaceutical preparation for treating a terminal non-small cell lung cancer patient or a terminal non-small cell lung cancer patient with brain metastasis (e.g., a kit preparation or a combined preparation), wherein the preparation comprises Ubenimex and Afatinib at doses significantly lower than typical doses and exerts therapeutic effects equivalent to or higher than the effects achieved by Afatinib at a typical dose, while rarely causing adverse effects; use of a low dose of Ubenimex and a low dose of Afatinib in the manufacture of the combined pharmaceutical preparation used for treating such patient; and a method for treatment of the cancer comprising administering the combined pharmaceutical preparation to the patient.

Abstract: An object of the present invention is to provide a new means for treating or ameliorating a blood cancer patient, wherein the new means has high effect and few side effects. The present invention relates to a combined medicine for use in a method for treating or ameliorating a blood cancer patient, comprising 4-amino-1-(2-cyano-2-deoxy-?-D-arabinofuranosyl)-2(1H)-pyrimidinone or a salt thereof and venetoclax or a salt thereof.

Abstract: An object of the present invention is to provide a method for stabilizing a substance DFP-11207 sensitive to humidity and unstable at high humidity, and a stabilized preparation thereof, and more specifically, provide a capsule preparation for treating cancer, containing DFP-11207 or a pharmaceutically acceptable salt thereof and a hygroscopic agent.

Abstract: An object of the present invention is to provide a highly effective method for treatment/remission of cancer, and prevention of recurrence/metastasis of cancer at low cost and with few side effects. A composition containing a urinary alkalinization agent, for use in treatment or remission of cancer, or prevention of recurrence or metastasis of cancer.

Abstract: The present invention aims at providing novel means for administering Venetoclax, wherein the means reduces the burden on a patient caused by taking Venetoclax and achieves a good balance between the effect and safety of Venetoclax. The present invention relates to a water-soluble macromolecular derivative that includes a plurality of Venetoclaxs, each Venetoclax being linked to a terminal carboxyl group of a multi-arm water-soluble polymer via an amide bond.

Abstract: An object of the present invention is to provide a method for stabilizing a substance DFP-11207 sensitive to humidity and unstable at high humidity, and a stabilized preparation thereof, and more specifically, provide a capsule preparation for treating cancer, containing DFP-11207 or a pharmaceutically acceptable salt thereof and a hygroscopic agent.

Abstract: An object of the present invention is to provide a new means for treating or ameliorating a blood cancer patient, wherein the new means has high effect and few side effects. The present invention relates to a combined medicine for use in a method for treating or ameliorating a blood cancer patient, comprising 4-amino-1-(2-cyano-2-deoxy-?-D-arabinofuranosyl)-2(1H)-pyrimidinone or a salt thereof and venetoclax or a salt thereof.

Abstract: The present invention relates to a pharmaceutical composition comprising a citrate salt for use in enhancing the effect of an anticancer drug.

Abstract: The present invention aims at providing novel means for administering Venetoclax, wherein the means reduces the burden on a patient caused by taking Venetoclax and achieves a good balance between the effect and safety of Venetoclax. The present invention relates to a water-soluble macromolecular derivative that includes a plurality of Venetoclaxs, each Venetoclax being linked to a terminal carboxyl group of a multi-arm water-soluble polymer via an amide bond.

Abstract: The present application provides a pharmaceutical composition for use in treatment or remission of patients with chronic myelogenous leukemia, wherein the composition comprises, as active ingredients, (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or a pharmacologically acceptable salt thereof, and 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide or a pharmacologically acceptable salt thereof, both of which are used at low doses.

Abstract: The present invention relates to a pharmaceutical composition comprising a citrate salt for use in enhancing the effect of an anticancer drug.

Abstract: An object of the present invention is to provide a highly effective method for treatment/remission of cancer, and prevention of recurrence/metastasis of cancer at low cost and with few side effects. A composition containing a urinary alkalinization agent, for use in treatment or remission of cancer, or prevention of recurrence or metastasis of cancer.

Abstract: An object of the present invention is to provide a method for treatment or prevention of cancer, which not only exerts a great effect at low cost but also has few side effects. A combination drug containing a urinary alkalinization agent and vitamin C or a combination drug containing a urinary alkalinization agent, vitamin C and metformin for use in treatment or remission of cancer.

Abstract: The present application provides a pharmaceutical composition for use in treatment or remission of patients with chronic myelogenous leukemia, wherein the composition comprises, as active ingredients, (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or a pharmacologically acceptable salt thereof, and 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide or a pharmacologically acceptable salt thereof, both of which are used at low doses.

Abstract: The present application provides a pharmaceutical composition for use in treatment or remission of patients with chronic myelogenous leukemia, wherein the composition comprises, as active ingredients, (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or a pharmacologically acceptable salt thereof, and 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide or a pharmacologically acceptable salt thereof, both of which are used at low doses.

Abstract: An object of the present invention is to provide a novel treatment method with fewer side effects for elderly cancer patients and terminal cancer patients. A pharmaceutical composition for treating or putting an elderly or a terminal cancer patient into remission, comprising, as an active ingredient, (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or a pharmacologically acceptable salt thereof.

Abstract: Provided is a new therapeutic agent for a malignant tumor, which is highly safe, sustains an antitumor effect, and can improve the means for administration and the number of times of administration. Disclosed is a compound of Formula (1), or a salt thereof: C[CH2O(CH2CH2O)mCH2CO—R1—R2]4??(1) wherein R1 represents a single bond, —N(R3)(CH2)n1CO—, or —N(R4)(CH2)n2N (R5)CO(CH2)n3CO—; R2 represents a group of Formula (a), (b), (c), (d), (e), or (f): m represents a number of from 10 to 1,000; and an arrow represents a bonding site.

Abstract: An object of the present invention is to provide a novel treatment method with fewer side effects for elderly cancer patients and terminal cancer patients. A pharmaceutical composition for treating or putting an elderly or a terminal cancer patient into remission, comprising, as an active ingredient, (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or a pharmacologically acceptable salt thereof.

Abstract: An object of this invention is to provide a novel delivery means that enables efficient delivery of an active ingredient to a target cell. Such objective is attained by a lipoplex comprising dioleylphosphatidylethanolamine (DOPE), phosphatidylcholine, a cationic lipid, and an RNAi molecule and an industrial method for producing the same.

Abstract: Provided is a new therapeutic agent for a malignant tumor, which is highly safe, sustains an antitumor effect, and can improve the means for administration and the number of times of administration. Disclosed is a compound of Formula (1), or a salt thereof: C[CH2O(CH2CH2O)nCH2CO—R1—R2]4 ??(1) wherein R1 represents a single bond, —N(R3)(CH2)n1CO—, or —N(R4)(CH2)n2N (R5)CO(CH2)n3CO—; R2 represents a group of Formula (a), (b), (c), (d), (e), or (f): m represents a number of from 10 to 1,000; and an arrow represents a bonding site.